2024NSFSC0637/Natural Science Foundation of Sichuan Province[Grants and Funding] - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Year	Number of Results
2024	3
2025	2

Page 1

Neoadjuvant therapy of sequential TACE, camrelizumab, and apatinib for single huge hepatocellular carcinoma (NEO-START): study protocol for a randomized controlled trial.

Hao Y, Xie F, Zhou Y, Li C, Zhang X, Shen J, Yao M, Sun X, Zhou J, Wen T, Peng W. Hao Y, et al. Trials. 2024 Jul 19;25(1):490. doi: 10.1186/s13063-024-08340-1. Trials. 2024. PMID: 39030637 Free PMC article.

ASO Author Reflections: Achievements of Textbook Outcomes for Hepatocellular Carcinoma Patients After Liver Resection: The Role of the Number of Metabolic Syndrome Risk Factors.

Qiu ZC, Li C. Qiu ZC, et al. Ann Surg Oncol. 2025 Jan;32(1):452-453. doi: 10.1245/s10434-024-16416-0. Epub 2024 Oct 28. Ann Surg Oncol. 2025. PMID: 39467972 No abstract available.

Association of the Number of Concurrent Metabolic Syndrome Risk Factors with Textbook Outcomes Following Liver Resection for Patients with Hepatocellular Carcinoma: A Multicenter Study.

Qiu ZC, Dai JL, Zhang Y, Xie F, Yu Y, Leng SS, Wen TF, Li C. Qiu ZC, et al. Ann Surg Oncol. 2025 Jan;32(1):399-407. doi: 10.1245/s10434-024-16343-0. Epub 2024 Oct 7. Ann Surg Oncol. 2025. PMID: 39373921

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year